Recent advances in the ARID family: Focusing on roles in human cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 315-324

  Lin, Chen ^a   Song, Wei ^b   Bi, Xinyu ^a   Zhao, Jianjun ^a   Huang, Zhen ^a   Li, Zhiyu ^a   Zhou, Jianguo ^a   Cai, Jianqiang ^a   Zhao, Hong ^a  

^a Hospital of Cancer   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

AT rich interaction domain; Cancer related signaling pathway; Human cancer; Potential targets; Therapy

Indexed keywords

ANDROGEN RECEPTOR; ARID1 PROTEIN; ARID1A PROTEIN; ARID1B PROTEIN; ARID2 PROTEIN; ARID3 PROTEIN; ARID3A PROTEIN; ARID3B PROTEIN; ARID3C PROTEIN; ARID4 PROTEIN; ARID4B PROTEIN; ARID5 PROTEIN; ARID5A PROTEIN; ARID5B PROTEIN; AT RICH INTERACTION DOMAIN PROTEIN; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; JARID1 PROTEIN; JARID1B PROTEIN; JARID1C PROTEIN; JARID1D PROTEIN; JARID2 PROTEIN; NUCLEAR PROTEIN; RETINOBLASTOMA BINDING PROTEIN 1; RETINOBLASTOMA BINDING PROTEIN 2; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA BINDING; GENE SEQUENCE; HUMAN; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; NEOPLASM; PROTEIN STRUCTURE; TRANSCRIPTION REGULATION;

EID: 84896711876     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S57023     Document Type: Article

References (115)

1. Wilsker D, Probst L, Wain HM, Maltais L, Tucker PW, Moran E. Nomenclature of the ARID family of DNA-binding proteins. Genomics. 2005;86(2):242-251.
2. Dallas PB, Pacchione S, Wilsker D, Bowrin V, Kobayashi R, Moran E. The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol Cell Biol. 2000;20(9):3137-3146.
3. Wilsker D, Patsialou A, Dallas PB, Moran E. ARID proteins: A diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 2002;13(3):95-106.
4. Wang XM, Nagl NG, Wilsker D, et al. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochemical. 2004;383:319-325.
5. Hurlstone AF, Olave IA, Barker N, van Noort M, Clevers H. Cloning and characterization of hELD/OSA1, a novel BRG1 interacting protein. Biochem J. 2002;364(Pt 1):255-264.
6. Nagl NG, Patsialou A, Haines DS, Dallas PB, Beck GR, Moran E. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 2005;65(20):9236-9244.
7. Guan B, Gao M, Wu C-H, Wang T-L, Shih I-M. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia. 2012;14(10):986-993.
8. Wang X, Nagl NG Jr, Flowers S, Zweitzig D, Dallas PB, Moran E. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer. 2004;112(4):636.
9. Van Rechem C, Boulay G, Leprince D. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun. 2009;385(4):586-590.
10. Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718-6727.
11. Mamo A, Cavallone L, Tuzmen S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 2012;31(16):2090-2100.
12. Wang D-d, Chen Y-b, Pan K, et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One. 2012;7(7).
13. Abe H, Maeda D, Hino R, et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Archiv. 2012; 461(4):367-377.
14. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22(8):1310-1315.
15. Sausen M, Leary RJ, Jones S, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013;45(1):12-17.
16. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012;25(2):282-288.
17. Werner HMJ, Berg A, Wik E, et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol. 2013;26(3):428-434.
18. Samartzis EP, Samartzis N, Noske A, et al. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod Pathol. 2012;25(6):885-892.
19. Katagiri A, Nakayama K, Rahman MT, et al. Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix. Int J Gynecol Cancer. 2012;22(2):208-212.
20. Nagl NG, Wang XM, Patsialou A, Van Scoy M, Moran E. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. Embo J. 2007;26(3):752-763.
21. Khursheed M, Kolla JN, Kotapalli V, et al. ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. Brit J Cancer. 2013;108(10):2056-2062.
22. Yan ZJ, Cui KR, Murray DM, et al. PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes Dev. 2005;19(14):1662-1667.
23. Zhao H, Wang J, Han Y, et al. ARID2: a new tumor suppressor gene in hepatocellular carcinoma. Oncotarget. 2011;2(11):886-891.
24. Manceau G, Letouze E, Guichard C, et al. Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. Int J Cancer. 2013;132(9):2217-2221.
25. Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 2011;43(9):828-829.
26. Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44(7): 760-764.
27. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399-405.
28. Wilkins C, Woodward J, Lau DTY, et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2013; 57(2):461-469.
29. Iwahara J, Clubb RT. Solution structure of the DNA binding domain from Dead ringer, a sequence-specific AT-rich interaction domain (ARID). Embo J. 1999;18(21):6084-6094.
30. Webb CF, Smith EA, Medina KL, Buchanan KL, Smithson G, Dou SS. Expression of bright at two distinct stages of B lymphocyte development. J Immunol. 1998;160(10):4747-4754.
31. Ma KW, Araki K, Ichwan SJA, Suganuma T, Tamamori-Adachi M, Ikeda MA. E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53. Mol Cancer Res. 2003; 1(6):438-444.
32. Lestari W, Ichwan SJA, Otsu M, et al. Cooperation between ARID3A and p53 in the transcriptional activation of p21WAF1 in response to DNA damage. Biochem Biophys Res Commun. 2012;417(2):710-716.
33. Peeper DS, Shvarts A, Brummelkamp T, et al. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol. 2002;4(2):148-153.
34. Fukuyo Y, Mogi K, Tsunematsu Y, Nakajima T. E2FBP1/hDril1 modulates cell growth through downregulation of promyelocytic leukemia bodies. Cell Death Differ. 2004;11(7):747-759.
35. Fukuyo Y, Takahashi A, Hara E, Horikoshi N, Pandita TK, Nakajima T. E2FBP1 antagonizes the p16(INK4A)-Rb tumor suppressor machinery for growth suppression and cellular senescence by regulating promyelocytic leukemia protein stability. Int J Oral Sci. 2011;3(4):200-208.
36. An GY, Miner CA, Nixon JC, et al. Loss of bright/ARID3a function promotes developmental plasticity. Stem Cells. 2010;28(9):1560-1567.
37. Puissegur MP, Eichner R, Quelen C, et al. B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. Leukemia. 2012;26(10):2224-2232.
38. Numata S, Claudio PP, Dean C, Giordano A, Croce CM. Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product. Cancer Res. 1999;59(15):3741-3747.
39. Dahl KDC, Dahl R, Kruichak JN, Hudson LG. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia. 2009;11(11):U1208-U1124.
40. Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE. miR-125b targets ARID3B in breast cancer cells. Cell Struct Funct. 2012;37(1):27-38.
41. Kobayashi K, Jakt LM, Nishikawa SI. Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn. Oncogene. 2013;32(21): 2640-2648.
42. Joseph S, Deneke VE, Dahl KDC. ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death. PLoS One. 2012;7(7).
43. Kim D, Tucker PW. A regulated nucleocytoplasmic shuttle contributes to Bright's function as a transcriptional activator of immunoglobulin genes. Mol Cell Biol. 2006;26(6):2187-2201.
44. Tidwell JA, Schmidt C, Heaton P, Wilson V, Tucker PW. Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription. Mol Immunol. 2011;49(1-2):260-272.
45. Gong WB, Zhou T, Mo JJ, Perrett S, Wang JF, Feng YG. Structural insight into recognition of methylated histone tails by retinoblastoma-binding protein 1. J Biol Chem. 2012;287(11):8531-8540.
46. Lai A, Kennedy BK, Barbie DA, et al. RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest. Mol Cell Biol. 2001;21(8):2918-2932.
47. Meehan WJ, Samant RS, Hopper JE, et al. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem. 2004;279(2):1562-1569.
48. Cao J, Gao T, Giuliano AE, Irie RF. Recognition of an epitope of a breast cancer antigen by human antibody. Breast Cancer Res Treat. 1999;53(3):279-290.
49. Wu MY, Eldin KW, Beaudet AL. Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. J Natl Cancer Inst. 2008;100(17):1247-1259.
50. Cao JN, Gao TW, Stanbridge EJ, Irie R. RBP1L1, a retinoblastoma-binding protein-related gene encoding an antigenic epitope abundantly expressed in human carcinomas and normal testis. J Natl Cancer Inst. 2001;93(15):1159-1165.
51. Winter SF, Lukes L, Walker RC, Welch DR, Hunter KW. Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis. PLoS Genetics. 2012;8(5).
52. Cui DX, Jin GQ, Gao TW, et al. Characterization of BRCAA1 and its novel antigen epitope identification. Cancer Epidem Biomar. 2004;13(7):1136-1145.
53. Huang TH, Oka T, Asai T, et al. Repression by a differentiation-specific factor of the human cytomegalovirus enhancer. Nucleic Acids Res. 1996;24(9):1695-1701.
54. Masuda K, Ripley B, Nishimura R, et al. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc Natl Acad Sci U S A. 2013;110(23):9409-9414.
55. Masuda K, Ripley B, Kishimoto T. ARID5a is an IL-6 mRNA stability protein. Chlorpromazine mediates its inhibitory effect on IL-6 production in macrophages through inhibition of ARID5A expression. Cytokine. 2012;59(3):544-544.
56. Joshi P, Greco TM, Guise AJ, et al. The functional interactome landscape of the human histone deacetylase family. Mol Syst Biol. 2013;9:672.
57. Xu H, Cheng C, Devidas M, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2012;30(7):751-757.
58. Rudant J, Orsi L, Bonaventure A, et al. Are ARID5B and IKZF1 polymorphisms also associated with childhood acute myeloblastic leukemia: the ESCALE study (SFCE)? Leukemia. 2013;27(3): 746-748.
59. Linabery AM, Blommer CN, Spector LG, Davies SM, Robison LL, Ross JA. ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk Res. 2013;37(8):936-942.
60. Peyrouze P, Guihard S, Grardel N, et al. Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. Br J Haematol. 159(5):599-602.
61. Wang Y, Chen J, Li J, et al. Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population. Gene. 2013;524(2): 203-207.
62. Yang W, Trevino LR, Yang JJ, et al. ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia. 2010;24(4):894-896.
63. Allis CD, Berger SL, Cote J, et al. New nomenclature for chromatin-modifying enzymes. Cell. 2007;131(4):633-636.
64. Takeuchi T, Watanabe Y, Takano-Shimizu T, Kondo S. Roles of jumonji and jumonji family genes in chromatin regulation and development. Dev Dyn. 2006;235(9):2449-2459.
65. Shi XB, Hong T, Walter KL, et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature. 2006; 442(7098):96-99.
66. Iwase S, Lan F, Bayliss P, et al. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell. 2007;128(6):1077-1088.
67. Huang F, Chandrasekharan MB, Chen YC, Bhaskara S, Hiebert SW, Sun ZW. The JmjN domain of Jhd2 is important for its protein stability, and the plant homeodomain (PHD) finger mediates its chromatin association independent of H3K4 methylation. J Biol Chem. 2010;285(32):24548-24561.
68. Benevolenskaya EV, Murray HL, Branton P, Young RA, Kaelin WG Jr. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell. 2005;18(6):623-635.
69. Liefke R, Oswald F, Alvarado C, et al. Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex. Genes Dev. 2010;24(6):590-601.
70. Christensen J, Agger K, Cloos PAC, et al. RBP2 belongs to a family of demethylases, specific for tri- and dimethylated lysine 4 on histone 3. Cell. 2007;128(6):1063-1076.
71. Chicas A, Kapoor A, Wang X, et al. H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc Natl Acad Sci U S A. 2012;109(23): 8971-8976.
72. Ge Z, Li WJ, Wang N, et al. Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. Faseb J. 2010;24(2):579-586.
73. Wang GG, Song JK, Wang ZX, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2009;459(7248):U847-U846.
74. Lin W, Cao J, Liu J, et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011;108(33):13379-13386.
75. van Zutven LJCM, Onen E, Velthuizen SCJM, et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer. 2006;45(5):437-446.
76. Sharma SV, Lee DY, Li BH, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80.
77. Yan H, Chen X, Zhang QP, et al. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44(+) cells and evidence for epigenetic mechanisms. PLoS One. 2011;6(9):e24397.
78. Roesch A, Becker B, Meyer S, et al. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol. 2005;18(9):1249-1257.
79. Lu PJ, Sundquist K, Baeckstrom D, et al. A novel gene (PLU-1) containing highly conserved putative DNA chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem. 1999;274(22):15633-15645.
80. Roesch A, Becker B, Meyer S, et al. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol. 2005;18(9):1249-1257.
81. Hayami S, Yoshimatsu M, Veerakumarasivam A, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer. 2010;9:5.
82. Xiang Y, Zhu Z, Han G, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A. 2007;104(49):19226-19231.
83. Sun L-L, Sun X-X, Xu X-E, et al. Overexpression of Jumonji AT-rich interactive domain 1B and PHD finger protein 2 is involved in the progression of esophageal squamous cell carcinoma. Acta Histochemica. 2013;115(1):56-62.
84. Yamane K, Tateishi K, Klose RJ, et al. PLU-1 is an H3K4 dernethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25(6):801-812.
85. Scibetta AG, Santangelo S, Coleman J, et al. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol 2007; 27(20):7220-7235.
86. Li Q, Shi L, Gui B, et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011;71(21):6899-6908.
87. Catchpole S, Spencer-Dene B, Hall D, et al. PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int J Oncol. 2011;38(5):1267-1277.
88. Nijwening JH, Geutjes EJ, Bernards R, Beijersbergen RL. The histone demethylase jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-Target genes in MEFs during senescence. PLoS One. 2011;6(9).
89. Ohta K, Haraguchi N, Kano Y, et al. Depletion of JARID1B induces cellular senescence in human colorectal cancer. Int J Oncol. 2013;42(4):1212-1218.
90. Roesch A, Becker B, Schneider-Brachert W, Hagen I, Landthaler M, Vogt T. Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. J Invest Dermatol. 2006;126(8):1850-1859.
91. Roesch A, Mueller AM, Sterapfl T, Moehle C, Landthaler M, Vogt T. RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer. 2008;122(5):1047-1057.
92. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141(4):583-594.
93. Jensen LR, Amende M, Gurok U, et al. Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation. Am J Hum Genet. 2005;76(2):227-236.
94. Abidi FE, Holloway L, Moore CA, et al. Mutations in JARID1C are associated with X-linked mental retardation, short stature and hyperreflexia. J Med Genet. 2008;45(12):787-793.
95. Santos C, Laia RR, Madrigal I, Badenas C, Pineda M, Mila M. A novel mutation in JARID1C gene associated with mental retardation. Eur J Hum Genet. 2006;14(5):583-586.
96. Kim TD, Shin S, Janknecht R. Repression of Smad3 activity by histone demethylase SMCX/JARID1C. Biochem Biophys Res Commun. 2008;366(2):563-567.
97. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463(7279):360-363.
98. Niu X, Zhang T, Liao L, et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene. 2012;31(6):776-786.
99. Wang W, Meadows LR, Denhaan JMM, et al. Human H-Y - a male-specific histocompatibility antigen derived from the smcy protein. Science. 1995;269(5230):1588-1590.
100. Lau YFC, Zhang JQ. Expression analysis of thirty one Y chromosome genes in human prostate cancer. Mol Carcinogen. 2000;27(4): 308-321.
101. Patsialou A, Wilsker D, Moran E. DNA-binding properties of ARID family proteins. Nucleic Acids Res. 2005;33(1):66-80.
102. Shirato H, Ogawa S, Nakajima K, et al. A jumonji (Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9. J Biol Chem. 2009;284(2):733-739.
103. Toyoda M, Kojima M, Takeuchi T. Jumonji is a nuclear protein that participates in the negative regulation of cell growth. Biochem Biophys Res Commun. 2000;274(2):332-336.
104. Puda A, Milosevic JD, Berg T, et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2012;87(3):245-250.
105. Bolisetty MT, Dy G, Tam W, Beemon KL. Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J Virol. 2009;83(23):12009-12017.
106. Kortschak RD, Tucker PW, Saint R. ARID proteins come in from the desert. Trends Biochem Sci. 2000;25(6):294-299.
107. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470-1473.
108. Wu RC, Jiang M, Beaudet AL, Wu MY. ARID4A and ARID4B regulate male fertility, a functional link to the AR and RB pathways. Proc Natl Acad Sci U S A. 2013;110(12):4616-4621.
109. Sayegh J, Cao J, Zou MR, et al. Identification of small molecule inhibitors of jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013;288(13):9408-9417.
110. Jones S, Wang T-L, Shih I-M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228-231.
111. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532-1543.
112. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. May 2012; 44(5):570-574.
113. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219-1223.
114. Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33(1):100-103.
115. Letunic I, Doerks T, Bork P. SMART 7: recent updates to the protein domain annotation resource. Nucleic Acids Res. 2012;40(Database issue):D302-D305.